This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2012
  • /
  • 09
  • /
  • FDA approves Afinitor Disperz (Novartis) for SEGA ...
Drug news

FDA approves Afinitor Disperz (Novartis) for SEGA Tumours

Read time: 1 mins
Last updated:2nd Sep 2012
Published:2nd Sep 2012
Source: Pharmawand
The FDA has on 29 August 2012 approved Afinitor Disperz (everolimus tablets for oral suspension; Novartis), a new pediatric dosage form of Afinitor (everolimus) indicated for treatment of Tuberous Sclerosis Complex (TSC) in patients aged >1 year who are diagnosed with Subependymal Giant Cell Astrocytoma (SEGA) that cannot be treated with surgery. Afinitor Disperz is the first approved pediatric-specific dosage form developed for the treatment of a pediatric tumor. Prior to approval of this new dosage form, Afinitor was recommended for use only in patients aged >3 years. In 2010, Afinitor was granted accelerated approval to treat SEGA in patients with TSC. Afinitor Disperz dissolves easily in a small volume of water and is available in smaller dose increments than the adult dosage form.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.